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Objective: To develop disease-specific recommendations for the diagnosis andmanagement of eosinophilic gran-
ulomatosis with polyangiitis (Churg–Strauss syndrome) (EGPA).
Methods: The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3
nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using amodified Delphi pro-
cess, a list of 40 questionswas elaborated by 2members and sent to all participants prior to themeeting. Concur-
rently, an extensive literature search was undertaken with publications assigned with a level of evidence
according to accepted criteria. Drafts of the recommendations were circulated for review to all members until
final consensus was reached.
Results: Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment andmonitoring of
EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm
antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these rec-
ommendations was also reviewed.
Discussion: These recommendations aim to give physicians tools for effective and individual management of
EGPA patients, and to provide guidance for further targeted research.© 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved., American College of Rheumatology; ANCAs, antineutrophil cytoplasm antibodies; BVAS, BirminghamVasculitis Activity Score;
ear, nose & throat; EGPA, eosinophilic granulomatosiswith polyangiitis (Churg–Strauss); ELISA, enzyme-linked immunosorbent
Five-Factor Score;GI, gastrointestinal;HE, hypereosinophilia;HES, hypereosinophilic syndromes; IL, interleukin; IV, intravenous;
onists;MPO,myeloperoxidase; PR3, proteinase-3; SNV, systemic necrotizing vasculitis; VTEs, venous thromboembolic events.
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Table 1
Level of evidence of the literature search, according to the Grading of Recommendations
Assessment, Development and Assessment (GRADE) guidelines [9].
Code Quality of
evidence
Definition
A High Further research is very unlikely to change our confidence
in the estimate of effect.
• Several high-quality studies with consistent results
• In special cases: one large, high-quality multi-center trial
B Moderate Further research is likely to have an important impact on
our confidence in the estimate of effect and may change the
estimate.
• One high-quality study
• Several studies with some limitations
C Low Further research is very likely to have an important impact
on our confidence in the estimate of effect and is likely to
change the estimate.
• One or more studies with severe limitations
D Very Low Any estimate of effect is very uncertain.
• Expert opinion
• One or more studies with very severe limitations
• No direct research evidence
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Churg–Strauss syndrome, recently renamed eosinophilic granuloma-
tosis with polyangiitis (EGPA) [1], is a systemic necrotizing vasculitis
(SNV) that affects small-to-medium-sized vessels. In 2009, the
European League Against Rheumatism (EULAR) published recommenda-
tions for themanagement of small- andmedium-sized-vessel vasculitides
[2] that continue to delineate the standard of care for EGPA patients.
Much progress has been made over the past 30 years in understanding,
redefining and treating SNV. Although EGPA belongs to the spectrum of
antineutrophil cytoplasm antibody (ANCA)-associated vasculitides
(AAV), it differs from granulomatosis with polyangiitis (Wegener's) and
microscopic polyangiitis because of its association with severe asthma,
and blood and tissue eosinophilia. ANCA-positivity ranges from 30–70%
of EGPA patients but is usually less frequently observed than in other
AAV [3–7]. EGPA also shares some characteristics with hypereosinophilic
syndromes (HES).
Despite the increasing number of high-quality clinical trials con-
ducted on AAV and progress towards consensus approaches to
treating HES [8], an unmet need remains for consensus guidelines
for EGPA diagnosis and management. To address this need, the
European Respiratory Society and the Foundation for the Develop-
ment of Internal Medicine in Europe commissioned the EGPA Con-
sensus Task Force to organize several meetings between 2009 and
2013 aimed at establishing recommendations for the definition,
diagnosis, investigation and management of EGPA.
2. Methods
The Task Force, convened by JFC and LG, comprised 8
pulmonologists (EB, JFC, KD, MH, MW, RL, US, VC), 6 internists (AM,
BD, CP, LG, LM, MG), 4 rheumatologists (CB, JH, WG, PM), 3 nephrolo-
gists (AV, DJ, RAS), 1 pathologist (CJ) and 1 allergist (PB) from 6 coun-
tries. MG was appointed to conduct the literature search and draft the
manuscript. A list of 40 questions, based on a literature search for mul-
tiple terms referencing EGPA and elaborated by 2 committee members
(CP, LG) and sent to all Task Force members prior to the final meeting
held on 13 April 2013 in Paris, guided the meeting agenda (see Online
Supplement). For each question, the Task Force members' answers
and comments were collected and synthesized into a draft manuscript
that was recirculated until consensus was reached.
Therapeutic intervention statements presented by the group were
classified according to GRADE-method-defined levels of evidence [9]
(Table 1). When evidence was low-grade and/or data contradictory,
the recommendationswere formed based on the opinions and practices
of Task Force members.
3. The 22 EGPA Consensus Task Force recommendations (Table 2)
[evidence level]
Each entry is followed by the procedural approach for physicians.
1 EGPA should be managed in collaboration with, or in, centers with
established expertise in the management of small- and medium-
sized-vessel vasculitides.
EGPA is a rare disease. Its prevalence ranges from 10.7–13 cases/
million inhabitants [10–12], with an annual incidence of 0.5–6.8
new cases/million inhabitants [13,14]. Although its incidence is
higher among asthmatic patients [15,16], EGPA remains poorly un-
derstood and often goes unrecognized bymost physicians. Thus, be-
cause inappropriate therapeutic decisions impact the prognosis of
EGPA patients, disease-activity assessment and treatment should
be managed in collaboration with, or in, centers with expertise in
vasculitis management. Notably, in a 20-year retrospective study in-
volving N100 EGPA patients, expert disease management was asso-
ciated with increased life expectancy and less disease severity [17].2 As theminimal initial differential diagnosiswork-up,we recommend se-
rologic testing for toxocariasis and human immunodeficiency virus
(HIV), specific IgE and IgG dosages for Aspergillus spp., search for Asper-
gillus spp. in sputum and/or bronchoalveolar lavage fluid, tryptase and
vitamin B12 dosages, peripheral blood smear (looking for dysplastic eo-
sinophils or blasts) and chest computed-tomography (CT) scan; addi-
tional investigations should be guided by patient-specific clinical
findings and extensive search for causes of hypereosinophilia should
be considered.
When clinical manifestations include asthma, eosinophilia, pulmo-
nary infiltrates and sinus disease, accompanied by extrapulmonary
findings of vasculitis (e.g. purpura), andhistologic evidence of vascu-
litis (and/or eosinophilic infiltration and/or granulomatous inflam-
mation) [1], the EGPA diagnosis is usually straightforward. Indeed,
the main differential diagnoses (i.e., other AAV and polyarteritis
nodosa) are usually excluded, although eosinophilia occurs in vascu-
litides other than EGPA.
However, before the onset of vasculitis and/or asthma, particularly in
ANCA-negative patients, EGPAmanifestations may mimic other dis-
eases (e.g., eosinophilic asthma, eosinophilic pneumonia or HES)
and an individual step-by-step diagnostic work-up is recommended
[18]. Notably, a recent multidisciplinary consensus report suggested
a novel classification of eosinophilic disorders [19] and diagnostic
evaluation could take this practical classification system into ac-
count.
A thorough investigation of the causes of reactive hypereosinophilia
(HE) is mandatory. Familial HE is extremely rare and can easily be
excluded. Prior symptoms and the use of databases (e.g. www.
pneumotox.com) can usually exclude drug-induced eosinophilia.
Also, because toxocariasis has a broad geographic distribution,
is often asymptomatic and can cause severe eosinophilia [20],
Toxocara serology is recommended. Further serologies for other
helminthic infections should be guided by the patient's country
of origin, travel history and dietary habits. Enzyme-linked immu-
nosorbent assay (ELISA) screening for antibodies to Strongyloides
stercoralis infection is recommended because this parasite can
cause severe hyperinfestation syndromes in glucocorticoid-
treated patients, even decades after infection [21]. HIV screening
Table 2
The 22 detailed recommendations for the diagnosis, follow-up and management of EGPA
with corresponding levels of evidence.
The EGPA Consensus Task Force recommendations Level of
evidence
1. EGPA should be managed in collaboration with, or in, centers with
established expertise in the management of small- and
medium-sized-vessel vasculitides
NA
2. We recommend serologic testing for toxocariasis and HIV, specific IgE
and IgG dosages for Aspergillus spp., search for Aspergillus spp. on a
sputum and/or bronchoalveolar lavage fluid, tryptase and vitamin B12
dosages, peripheral blood smear (looking for dysplastic eosinophils
or blasts) and chest CT scan as being the minimal initial differential
diagnosis work-up; additional investigations should be guided by
patient-specific clinical findings and extensive search for causes of
hypereosinophilia should be considered
NA
3. Obtaining biopsies from patients with suspected EGPA is encouraged NA
4. ANCA testing (with indirect immunofluorescence and ELISA) should
be done for patients with suspected EGPA
NA
5. There is currently no reliable biomarker to measure EGPA activity NA
6. Once EGPA is diagnosed, evaluating possible lung, kidney, heart, GI
and/or peripheral nerve involvements is recommended
NA
7. Definition of EGPA remission: the absence of a clinical systemic
manifestation (excluding asthma and/or ENT)
NA
8. Definition of EGPA relapse: the new appearance or recurrence or
worsening of clinical EGPA manifestation(s) (excluding asthma
and/or ENT) requiring the addition, change or dose increase of
glucocorticoids and/or other immunosuppressants
NA
9. Use of glucocorticoids is appropriate to achieve EGPA remission; the
dose prescribed should be ~1 mg/kg/day prednisone for patients with
organ- or life-threatening manifestations
A
10. Patients with life and/or organ-threatening disease manifestations
(i.e., heart, GI, central nervous system, severe peripheral
neuropathy, severe ocular disease, alveolar hemorrhage and/or
glomerulonephritis) should be treated with a remission-induction
regimen combining glucocorticoids and an additional immunosup-
pressant (e.g. cyclophosphamide)
B
11. Maintenance therapy (with azathioprine or methotrexate) is
recommended for patients with life- and/or organ-threatening
disease manifestations a remission-induction therapeutic regimen
C
12. Glucocorticoids alone may be suitable for patients without life-
and/or organ-threatening disease manifestations; additional
immunosuppression can be considered for selected patients for
whom the prednisone dose cannot be tapered to b7.5 mg/day after
3–4 months of therapy or patients with recurrent disease
C
13. Plasma exchanges are generally not effective in EGPA but can be
considered for selected patients with ANCA and rapidly progressive
glomerulonephritis or pulmonary–renal syndrome
D
14. Rituximab can be considered for selected ANCA-positive patients
with renal involvement or refractory disease
C
15. IVIg can be considered a second-line therapy for patients on
glucocorticoids (and/or other immunosuppressants) with EGPA flares
refractory to other treatments or during pregnancy; in the context of
drug-induced hypogammaglobulinemia with severe and/or recurrent
infections, Ig-replacement may be considered
C
16. Interferon-alpha may be reserved as a second- or third-line drug for
selected patients
C
17. LRA can be prescribed, if needed, for EGPA patients B
18. Vaccinations with inactivated vaccines and against influenza and
pneumococci should be encouraged; live-attenuated vaccines are
contraindicated in patients taking immunosuppressants, and/or ≥20
mg/day of prednisone
D
19. Implementation of patient educational programs is encouraged D
20. Patients with peripheral nerve involvement and motor
deficit(s) should routinely be referred to a physiotherapist
D
21. Patients should be advised to avoid tobacco smoke and irritants D
22. Venous thromboembolic events and pulmonary embolism should
be treated according to general guidelines for the management of
thromboembolic disease; it is unknown whether anticoagulation
should be prolonged in selected patients with persistent or recurring
disease activity
D
EGPA: eosinophilic granulomatosis with polyangiitis (Churg–Strauss); ANCAs: anti-
neutrophil cytoplasm antibodies; CT: computed tomography; EGPA: eosinophilic
granulomatosis with polyangiitis (Churg–Strauss); ELISA: enzyme-linked immuno-
sorbent assays; ENT: ear, nose & throat; HIV: human immunodeficiency virus; IVIg:
intravenous immunoglobulins; LRA: leukotriene-receptor antagonists; NA: not
applicable.
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is often mild. If the patient resides or has traveled in a region
where human T-lymphocyte virus-1 is endemic, serologic testing
for this retrovirus is recommended. When EGPA is suspected,
IgE- and IgG-specific antibodies to Aspergillus species and Asper-
gillus species in sputum and/or bronchoalveolar lavage fluid
should also be sought, especially when bronchiectasis is present.
Notably, in untreated patients, normal serum IgE levels eliminate
the diagnosis of allergic bronchopulmonary aspergillosis [22].
Paraneoplastic eosinophilia (namely in the setting of lung cancer,
cervical cancer, Hodgkin's or non-Hodgkin's T-cell lymphoma)
should also be investigated through patient and family history
(tobacco smoking, colorectal cancer), physical examination, lactate
dehydrogenase level, chest X-ray, abdominal ultrasound and, if nec-
essary, high-resolution thoracoabdominal CT scan. Finally, patients
with cutaneous lesions (e.g., skin rash and hives, eczema),
hypergammaglobulinemia and/or cyclic recurrent angioedema
(i.e., Gleich's syndrome) may have a lymphocytic variant reactive
HE (formerly L-HES) [23]. In that specific population, lymphocyte
immunophenotyping (to detect abnormal surface phenotypes in-
cluding CD3—CD4+, CD4+CD7— and CD3+CD4—CD8—) and analysis
of T-cell-receptor rearrangement are recommended, and should be
performed in laboratories with appropriate expertise. Serum
CCL17/TARC (thymus and activation-regulated cytokine) determi-
nation might also be useful in this setting but is not done routinely
[24].
Hepatomegaly, splenomegaly, anemia, thrombocytopenia and/or
the absence of response to glucocorticoids are suggestive of clonal
(neoplastic) HE. The latter is a heterogeneous group comprising
chronic eosinophilic leukemia (formerly themyeloproliferative var-
iant of HES) and other myeloid neoplasms (e.g., chronic myeloid
leukemia, systemic mastocytosis and myelodysplastic syndromes),
which can be associated with HE [19]. Screening for serum vitamin
B12 and tryptase levels is sensitive for neoplastic HE and is recom-
mended for all patients [25,26]. When that diagnosis is suspected,
testing for PDGFRA, PDGFRB, FGFR1, BCR/ABL1 fusion genes and
search for a Janus kinase-2 mutation could be helpful.
Idiopathic chronic eosinophilic pneumonia (formerly Carrington's
disease) is also part of the differential diagnosis of EGPA because
both entitiesmay beginwith chronic sinusitis, pulmonary infiltrates
and peripheral blood HE. However, chronic eosinophilic pneumonia
patients only rarely suffer from HE-associated systemic manifesta-
tions [27]. While the lung infiltrates of idiopathic chronic eosino-
philic pneumonia may be located peripherally on chest imaging,
this pattern is neither sensitive nor specific to chronic eosinophilic
pneumonia and can also be observed in EGPA. The possible overlap
of idiopathic chronic eosinophilic pneumonia and EGPA deserves
further investigation, and these entities could be part of the same
spectrum.
3 Obtaining biopsies from patients with suspected EGPA is encouraged.
While diagnostic criteria are lacking (a second Task Force paper
addressing this topic is in preparation), diagnosing EGPA implies
proven vasculitis or a strong clinical surrogate, but either can be
difficult to obtain. Within the clinical context of asthma with
eosinophilia, asthmawith systemic manifestations or even eosin-
ophilia with extrapulmonary disease, a biopsy demonstrating
small- or medium-sized-vessel vasculitis (e.g., fibrinoid necrosis,
leukocytoclasia or pauci-immune crescentic glomerulonephritis)
and/or a strong clinical surrogate of vasculitis strongly supports a
diagnosis of EGPA [28]. EGPA diagnosis implies a vasculitic fea-
ture but the selection of sites for biopsies depends on individual
patient characteristics and the likelihood of safely obtaining
tissue sample(s) that will be most definitive for a diagnosis.
Skin, nerve andmuscle are among themost common biopsied tis-
sues, but endomyocardial, renal and gastrointestinal (GI) biop-
sies may also be useful.
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be done for patients with suspected EGPA.
A perinuclear immunofluorescent pattern with ELISA detecting an-
tibodies to myeloperoxidase (MPO) is the most common EGPA
ANCA-positivity finding. Together, positive immunofluorescence
and ELISA are highly sensitive and specific for AAV diagnosis [29].
In the clinical context of asthma and eosinophilia, anti-MPO
ANCA-positivity is highly suggestive of EGPA but, conversely,
ANCA-negativity does not rule out its diagnosis. Importantly, a cyto-
plasmic ANCA-labeling pattern on immunofluorescence and ELISA
detection of anti-proteinase-3 (PR3) antibodies have been reported
in EGPA [4], but such results are quite unusual and, in this setting, an
EGPA diagnosis should be reviewed critically.
ANCA-test results define EGPA-patient subgroups. Cohort-study
findings suggest that ANCA status may reflect different EGPA phe-
notypes [4,5]. ANCA-positive patients are more likely to have a
“vasculitic” phenotypewith glomerulonephritis, mononeuritis mul-
tiplex and relapses. However, despite fewer relapses, the prognosis
of ANCA-negative patients is poorer, possibly because of their high
frequency of cardiomyopathy [30,31].
5 There is currently no reliable biomarker to measure EGPA activity.
Several groups have tried to assess the accuracy of biomarkers to de-
fine EGPA activity and predict relapses. Other than perhaps the total
eosinophil count, common laboratory tests (e.g., serum IgE, erythro-
cyte sedimentation rate and C-reactive protein (CRP)) are not con-
tributory [32]. IgE levels could be informative for patients with
refractory asthma when contemplating omalizumab administra-
tion. Also, the eosinophil cationic protein was correlated with dis-
ease activity in small series [33,34] but longitudinal data are scarce
[35].
Lastly, preliminary studies examined several novel biomarkers
(e.g., CCCL17/TARC, IgG4 and CCL26/eotaxin-3) [36–39], but their
routine determination is not yet recommended.
6 Once EGPA is diagnosed, evaluating possible lung, kidney, heart, GI and/
or peripheral nerve involvements is recommended.
Asthma is almost always present at EGPA onset. However, some pa-
tients may develop asthma in the weeks following vasculitis onset.
Thus, a complete pulmonary diagnostic evaluation, comprising
baseline chest imaging (i.e., high-resolution CT scan which is more
sensitive than plain radiography) and pulmonary function tests (at
least spirometry) are recommended at the time of EGPA diagnosis.
Complementary investigations should not delay treatment initia-
tion for life-threatening manifestations. Any identified abnormali-
ties in these investigations should subsequently be monitored
according to the patients' clinical status [40].
Kidney, heart and/or GI involvements are associated with poor
prognoses and mandate immunosuppressive therapy. Therefore,
these organmanifestations should be diagnosed early and screened
for regularly during follow-up [41].
Cardiac involvement is the leading cause of EGPA-patient deaths
[3,31] and basic cardiac investigations (chest imaging, electro-
cardiography, transthoracic echocardiography, N-terminal pro-
brain natriuretic peptide and troponin I measurements) are
recommended. New cardiac imaging technique (e.g., cardiac
magnetic resonance imaging and positron-emission-tomography
scan) seem to be more sensitive than the above-mentioned in-
vestigations [42–46], but the clinical significance of abnormali-
ties detected with those imaging modalities remains unclear.
Asymptomatic MRI abnormalities are most likely heart involve-
ment but should not yet engender treatment intensification
(e.g. cyclophosphamide). Patients with symptoms suggestive of
arrhythmia should undergo further investigation.
GI involvement, specifically ischemic disease, is predictive of
poor outcomes. Patients with abdominal pain, nausea, vomiting,
hematemesis, diarrhea, hematochezia and/or melena require ra-
diologic and/or endoscopic investigations. However, becauseabdominal pain is almost always present in SNV-related GI involve-
ment [47], routine screening of asymptomatic patients with abdom-
inal imaging or endoscopy studies is not recommended.
Renal function tests and urinalysis (for examination of proteinuria
and hematuria/casts) should be performed at disease onset and reg-
ularly during follow-up to screen for a renal disease flare, drug tox-
icity (e.g. cyclophosphamide) or help with drug–dose adjustments
(cyclophosphamide andmethotrexate). Ambulatory dipstick analy-
sis of morning urine samples by the patient is encouraged, in
addition to office or hospital-based renal function evaluations, uri-
nalyses and protein/creatinine ratios.
Additional diagnostic procedures should be performed as indi-
cated by symptoms or physical examination findings. Notably,
electromyography and nerve-conduction studies should be or-
dered when clinically indicated (i.e., when myalgias, muscle
weakness and/or peripheral neuropathy are present). Eye
involvement is rare and systematic examination by an ophthal-
mologist at EGPA diagnosis is not mandatory.
7 Definition of EGPA remission: the absence of a clinical systemic
manifestation (excluding asthma and/or ear, nose & throat (ENT)).
Systemic EGPA manifestations may have different clinical
courses. ENT manifestations and/or asthma flares may not neces-
sarily reflect vasculitis activity but are often part of the EGPA
course [3,4]. Immunosuppressants other than glucocorticoids
may control systemic EGPA features but not ENT manifestations
and/or asthma. In accordance with some studies [3,4], the Task
Force concluded that these symptoms be monitored separately.
Most Task Force members concurred that the EGPA-remission
definition excludes the control of asthma and/or non-specific
ENT manifestations. Also, the experts were unable to define an
upper eosinophil-count threshold during remission. The ideal
definition of remission would be the absence of clinical symp-
toms and biologic abnormalities in patients weaned off glucocor-
ticoids and immunosuppressants. Since such EGPA outcomes are
rare (15.7% in one series (3)), the majority of Task Force mem-
bers consideredminimal prednisone and/or immunosuppressant
dose(s) acceptable to define remission. The EULAR experts [2]
concluded that the definition of remission could include a mini-
mumprednisone dose of 7.5 mg/day to control systemic manifes-
tations; however, that arbitrarily fixed dose is debatable.
8 Definition of EGPA relapse: the new appearance or recurrence or
worsening of clinical EGPA manifestation(s) (excluding asthma
and/or ENT), requiring the addition, change or dose increase of glu-
cocorticoids and/or other immunosuppressants.
During the course of EGPA, asthma flares and/or ENT manifesta-
tions are frequent and multifactorial, and blood eosinophil
counts may fluctuate. Isolated transient and fully reversible loss
of asthma control with a clearly identified cause (e.g. viral infec-
tion), may occur in asthma of any cause, and should not be sys-
tematically considered an EGPA relapse. Most Task Force
members considered that isolated asthma or sinusitis exacerba-
tion with or without increased blood eosinophilia does not nec-
essarily imply a relapse per se but, nonetheless, warrants
therapy. These patients should be monitored closely because
these symptoms may be early signs of a vasculitis flare.
Conversely, eosinophilia is not a mandatory criterion for diag-
nosing a flare. Indeed, glucocorticoids, which are the cornerstone
of EGPA treatment, reduce the number of circulating eosinophils.
In addition, eosinophilic activity may occasionally be organ-
limited without blood eosinophilia.
The Task Force aimed to obtain a sharper definition of EGPA
relapse but, given the lack of stringent criteria, this goal was not
achieved.
9 Use of glucocorticoids is appropriate to achieve EGPA remission; the
dose prescribed should be ~1 mg/kg/day prednisone for patients
with organ- or life-threatening manifestations [A].
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presence of life-threatening symptoms, methylprednisolone
pulses (7.5–15 mg/kg/day) should be administered. As induction
therapy, we suggest starting prednisone at 1 mg/kg/day for
2–3 weeks, followed by gradual tapering (ideally down to
0.3 mg/kg/day after 3 months and 0.15 mg/kg/day after
6 months) to the minimal effective dose or, when possible, until
withdrawal. The maintenance glucocorticoid dose should be
adapted to tightly control each patient's needs to prevent re-
lapses of systemic manifestations and control asthma. Optimally,
this dose should be b7.5 mg/day to limit glucocorticoid-induced
side effects [17]. However, in a recent series [3], approximately
85% of EGPA patients required long-term prednisone (mean
dose 12.9 ± 12.5 mg/day) to control asthma, rhinitis and/or ar-
thralgias, thereby highlighting the need for glucocorticoid-
sparing therapies.
10 Patients with life- and/or organ-threatening disease manifestations
(i.e., heart, GI, central nervous system, severe peripheral neuropa-
thy, severe ocular disease, alveolar hemorrhage and/or glomerulo-
nephritis) should be prescribed a remission–induction regimen
combining glucocorticoids and another immunosuppressant (e.g.
cyclophosphamide) [B].
The Five-Factor Score (FFS) is a prognostic tool that consists of 5
items, 4 of which [age N65 years, heart and GI (i.e., hemorrhage,
infarction or pancreatitis), stabilized peak creatininemia
N150 μmol/L, each accorded +1 point] are associated with poor
prognoses, while the fifth (ENT manifestations) is associated
with better outcomes and its absence is scored +1 [41]. Adjunc-
tive cytotoxic drugs are recommended to treat FFS ≥ 1 high-risk
EGPA patients. However, unlike other AAV for which several ran-
domized–controlled trials have been conducted [48], no
randomized–controlled-trial results are available to support
this recommendation.
Furthermore, severe alveolar hemorrhage, eye involvement (albeit
rare in EGPA) and fulminant mononeuritis multiplex can be life-
threatening and/or carry poor functional prognoses. Thus, although
they are not part of the FFS [41], immunosuppressant (including
cyclophosphamide) use for these symptoms should be considered
[31].
Cyclophosphamide may be equally effective as continuous oral
therapy (2 mg/kg/day) or intravenous (IV) pulses. If pulse adminis-
tration is chosen, the first 3 infusions (15mg/kg or 0.6 g/m2) should
be given every 2 weeks, with a maximum of 1.2 g per infusion.
Pulses 3–6 at 15 mg/kg or 0.7 g/m2 can then be infused every
3weeks. Cyclophosphamide doses should be adjusted to renal func-
tion. While pulse administration may be associated with more re-
lapses [49], it might favor compliance and decrease long-term
morbidity and mortality [50], but prospective data are scarce. As
suggested by the preliminary CORTAGE trial results, patients
≥ 65 yearswith orwithout poor-prognosis factorsmight also benefit
from lower immunosuppressant doses to avoid drug-related side
effects [51].
Because serious side effects of cyclophosphamide may occur, physi-
cians should strive to prevent them. Because of gonadal toxicity,
semen cryopreservation and GnRH-analog treatment for women is
recommended [52]. By analogywith granulomatosis with polyangi-
itis (Wegener's), Pneumocystis jiroveci pneumonia prophylaxis with
co-trimoxazole (400 mg/day or 800 mg thrice weekly) should be
considered [53,54]. Lastly, regular screening for drug-induced neu-
tropenia is necessary.
11 Maintenance therapy (with azathioprine or methotrexate) is recom-
mended for patients with life- and/or organ-threatening disease mani-
festations after a remission–induction therapeutic regimen [C].
In a prospective study assessing the benefits of glucocorticoid-&-
cyclophosphamide induction for high-risk EGPA patients, overall
survival without maintenance therapy reached 97% and 92% at 5and 8 years, respectively [55]. However, relapse rates were also
high, 73.8% or 85.7% respectively, depending on whether patients
had received 6 or 12 cyclophosphamide pulses [55]. These observa-
tions suggested that, as with other AAV, EGPA patients would also
benefit from maintenance therapy to avoid relapses and allow glu-
cocorticoid tapering.
Maintenance therapy with an immunosuppressant can be started
2–3 weeks after the last cyclophosphamide pulse or a few days
after oral cyclophosphamide. Unlike other AAV [56–58], no
study has compared immunosuppressants for EGPAmaintenance
therapy. Since the CYCAZAREM trial (which did not include EGPA
patients) demonstrated that azathioprine (2 mg/kg/day) was as
effective as cyclophosphamide for preventing relapses, cyclo-
phosphamide is now used to induce vasculitis remission but not
for longer-term remission maintenance [56]. Other than azathio-
prine, methotrexate (10–30 mg/week, along with folic acid re-
placement, 10–30 mg/week) has also been used as a potent
remission-maintenance agent for AAV [58]. The optimal duration
of maintenance therapy remains unknown; 18–24 months fol-
lowing remission induction could be recommended. A recent
study established that ANCA-positivity, cutaneous manifesta-
tions and a low eosinophil count at the time of EGPA diagnosis
were predictive of relapse [3].
12 Glucocorticoids alone may be suitable for patients without life- and/or
organ-threatening diseasemanifestations; additional immunosuppres-
sion can be considered for selected patients for whom the prednisone
dose cannot be tapered to b7.5 mg/day after 3–4 months of therapy
or for patients with recurrent disease [C].
In the CHUSPAN study, treatment of FFS = 0 EGPA and
polyarteritis nodosa patients with glucocorticoids alone was
effective, achieving a 5-year survival rate of 96.8%. However,
one-third of the patients (especially those with peripheral neu-
ropathy) eventually required a cytotoxic agent, suggesting that
more patients might also benefit from early prescription of addi-
tional immunosuppression [31].
A recent retrospective study on FFS = 0 EGPA patients, who
could not have their prednisone dose lowered to b7.5 mg/day
after 3 months due to systemic manifestations and/or refractory
asthma and who received additional immunosuppressants, sug-
gested that these patients had low relapse rates and did not
develop more serious infectious events than patients from previ-
ous series [17]. However, whether cytotoxic drugs should be
added to regimens for patients unable to taper prednisone for
asthma and/or ENT manifestations remains unclear. The
CHUSPAN 2 trial (ClinicalTrials.gov NCT00647166) is currently
evaluating the effectiveness of adjunctive azathioprine for
FFS = 0 EGPA patients. Until additional data become available,
immunosuppressant prescription for this purpose should be
discussed on an individual basis.
13 Plasma exchanges are generally not effective in EGPA but can be
considered for selected ANCA-positive patients with rapidly pro-
gressive glomerulonephritis or pulmonary–renal syndrome [D].
Two randomized–controlled trials published in the mid-1990s
that enrolled EGPA patients with or without factors predicting
increased mortality risk failed to demonstrate that plasma ex-
change adjunction to standard therapy improved survival [59,
60]. However, whether plasma exchanges could be beneficial
for selected patients remains unknown. Currently available data
do not support their routine use. They should only be considered
for patients with severe diffuse alveolar hemorrhage [61] and
rapidly progressive, severe renal insufficiency. In this setting,
among patients with AAV, but not EGPA, plasma exchanges at-
tenuated end-stage renal disease and enhanced renal recovery
12 months after a flare [62], but long-term benefits are unclear
[63]. The use of plasma exchanges for severe AAV remains
under active investigation [64].
Table 3
Research topics.
Genetic studies on EGPA
Development of animal models
Identification of markers for early identification of patients with late-onset asthma
who will develop EGPA
Identification of reliable diagnostic biomarkers to differentiate eosinophilic asthma
vs. HES vs. vasculitis
Identification of reliable biomarkers to differentiate asthma flares from vasculitis
flares
Development of tools that specifically address clinical aspects of EGPA
Improving maintenance treatment to prevent relapses and reduce the
glucocorticoid burden
Optimize treatment(s) for patients with persistent asthma (mepolizumab vs.
omalizumab vs. lebrikizumab)
Development of an alternative to cyclophosphamide for patients with FFS ≥ 1 EGPA
Investigations of other drugs that are used to treat some forms of HES (e.g.
tyrosine-kinase inhibitors)
Determine the place of ANCA monitoring
Optimize the diagnostic strategy for and treatment of EGPA-related heart
involvement
Implementation of an international registry of EGPA patients
ANCAs: anti-neutrophil cytoplasm antibodies; EGPA: eosinophilic granulomatosis with
polyangiitis (Churg–Strauss); FFS: Five-Factor Score; HES: hypereosinophilic syndromes.
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with renal involvement or refractory disease [C].
Rituximab, a chimeric monoclonal antibody directed against the
B-lymphocyte, cell-surface CD20 protein, has been shown to be
as effective as cyclophosphamide at inducing remission of granu-
lomatosis with polyangiitis (Wegener's) and microscopic poly-
angiitis [65,66]. For maintenance, a prospective study's results
showed that rituximab was superior to azathioprine as mainte-
nance therapy [67]. However, those 3 trials did not include
EGPA patients. Data on rituximab use for EGPA, limited to case re-
ports [68,69] and case series [70–72], suggest that it is effective
and safe. Remission rates seemed to be higher for ANCA-
positive than ANCA-negative patients [72]. However, despite
concomitant administration of IV glucocorticoids, severe bron-
chospasms immediately after the first infusion have been report-
ed [73]. In addition to B-cell depletion, rituximab might have
other mechanisms of action. Notably, it was shown to diminish
T-cell interleukin (IL)-5 production [74]. More information is
needed regarding rituximab use for EGPA. Until then, although
not licensed for EGPA, using rituximab seems reasonable for
ANCA-positive patients with renal involvement or severe refrac-
tory disease, despite conventional therapy, for whom traditional
cytotoxic agents are contraindicated or undesirable (e.g., to pre-
vent cyclophosphamide-induced gonadal toxicity in younger pa-
tients and/or urinary bladder toxicity in those who have already
received high cumulative cyclophosphamide doses).
15 IV immunoglobulins (IVIg) can be considered a second-line therapy for
patients on glucocorticoids (and/or other immunosuppressants) with
EGPA flares refractory to other treatments or during pregnancy; in
the context of drug-induced hypogammaglobulinemia with severe
and/or recurrent infections, Ig-replacement may be considered [C].
Several case reports demonstrated the efficacy of high-dose IVIg
(i.e., 2 g/kg for 2–5-day cycles which can be repeated every
3–4 weeks) in naïve and previously treated EGPA patients [75,76].
In a small Japanese case series, EGPA-related heart involvement
and peripheral neuropathy seemed to respond well to this thera-
peutic strategy [77]. IVIg were also effective during pregnancy,
when glucocorticoids and azathioprine are the only authorized im-
munosuppressants [78]. A small study on 9 patients suggested that,
when added to conventional therapy, synchronized monthly plas-
ma exchange followed by IVIg cycles of could be beneficial [79].
Furthermore, although no strong data support this recommendation,
Ig replacement may be considered for patients with severe and/or
recurrent infections and drug-related hypogammaglobulinemia.
16 Interferon-alpha may be reserved as a second- or third-line therapy for
selected patients [C].
Although interferon-alpha achieved acceptable remission rates in a
small, prospective, open-label study [80], its effect was transient and
relapses were frequent after its discontinuation [81]. Because of nu-
merous side effects and development of new promising biologics,
interferon-alpha should be considered a second- or third-line drug.
17 Leukotriene-receptor antagonists (LRA) can be prescribed, if needed, for
EGPA patients [B].
Several early series suggested that LRA could have triggered or caused
EGPA [82,83]. That attribution remains controversial and review of
available evidence suggests that LRA do not directly cause EGPA
[84], and that EGPA onset after starting an LRA might be coincidental
to EGPA worsening or as a result of glucocorticoid-tapering unmasking
symptoms [85,86].
Whether LRA can be safely prescribed to EGPA patients remains contro-
versial but can be tried, if necessary, to treat asthma, with close moni-
toring. Further prospective studies are needed to address this issue.
18 Vaccination with inactivated vaccines and against influenza and pneu-
mococci should be encouraged; live-attenuated vaccines are contraindi-
cated in patients taking immunosuppressants and/or ≥20 mg/day of
prednisone [D].Exogenous factors might trigger EGPA. A few case reports, but no case–
control study, described EPGA onset after vaccination [87,88] or allergic
desensitization [89]. Infections are a burden in systemic AAV [90] and
represent approximately 25% of the causes of deaths during the first
year after their onset [91]. In a large population of vasculitis (including
EGPA) patients, vaccination against A/H1N1 influenza with a non-
adjuvant vaccine was effective and well-tolerated. No patient relapsed
following vaccination [92,93] but some patients' eosinophil counts
rose. To date, the benefit/risk ratio seems to favor vaccination of vascu-
litis patients. Other than live-attenuated vaccines,which are contraindi-
cated in patients taking immunosuppressants and/or ≥20 mg/day of
prednisone [94], the Task Force recommends that EGPA patients be vac-
cinated in the same manner as the general population, except possibly
patients who had an EGPA flare after a vaccination. In addition, vaccina-
tion against pneumococci and yearly vaccination against influenza
should be encouraged.
19 Implementation of patient educational programs is encouraged [D].
In a vasculitis referral center, educational programs have been effec-
tive at improving patients' knowledge of their disease [95]. Thus,
such programs may favor earlier diagnoses of flares and treatment
side effects, and contribute to better outcomes.
20 Patients with peripheral nerve involvement andmotor deficit(s) should
routinely be referred to a physiotherapist [D].
Although no specific data are available on physiotherapy and vasculitis,
the Task Force recommends, based on experience with other acquired
peripheral neuropathies [96,97], that patients with peripheral nerve in-
volvement andmotor deficit(s) be routinely referred to a physiotherapist.
21 Patients should be advised to avoid tobacco smoke and irritants [D].
Consistent with the guidelines for asthma diagnosis andmanagement
[98], we recommend that EGPA patients avoid tobacco smoke and
irritants, which may trigger asthma flares and reduce pulmonary
function.
22 Venous thromboembolic events (VTE) and pulmonary embolism
should be treated according to general guidelines for the manage-
ment of thromboembolic disease; it is unknown whether
anticoagulation should be prolonged in selected patients with per-
sistent or recurring disease activity [D].
AAV are associated with an increased risk of VTEs, which occur mainly
during active-disease phases [99]. In the largest published EGPA-patient
cohort [3], no VTE-frequency difference was observed between ANCA-
negative and ANCA-positive patients (20% vs. 8%, respectively, P =
0.77). No specific guidelines are available for VTEs and/or pulmonary
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guidelines for the management of pulmonary embolism and deep-vein
thromboses recommend 3–6 months of anticoagulation after a VTE
[100]. By analogy with HES [101], and in light of the thrombotic patho-
physiologicmechanisms involved in EGPA, it remains unknownwhether
anticoagulation duration should be prolonged in selected patients with
persistent or recurrent disease activity.4. Discussion
The Task Force members acknowledge that some of their recom-
mendations have low evidence levels because they were derived from
existing data on EGPA-related diseases, rather than EGPA itself, and/or
are opinion-based. Thus, future (especially prospective) EGPA-specific
studies are needed.
First, mepolizumab, a humanized monoclonal antibody targeting
IL5, themajor eosinophil-survival factor, is effective against eosinophilic
asthma [102,103] and, thus, holds promise for EGPA [104]. To date, the
results of only 2 pilot studies showed that mepolizumab successfully
treated refractory EGPA, thereby achieving glucocorticoid-sparing
[105], and maintained remission without further conventional immu-
nosuppression [106]. An international randomized placebo-controlled
trial on EGPA is ongoing (ClinicalTrials NCT02020889); its results are
eagerly awaited.
Next, whether ANCA-negative and ANCA-positive EGPA patients in-
deed represent the same disease entity and whether these subgroups
would benefit from distinct therapeutic strategies are debatable. Future
studies and updated recommendations should address these issues.
Lastly, these recommendations should not be considered definitive
guidelines but rather as consensus statements derived from up-to-
date data on EGPA. They are intended to give physicians tools for effec-
tive, individualized management of EGPA patients and to serve as a
starting point for future EGPA-targeted research. We identified 13
high-priority research topics (Table 3) and regular updates will be nec-
essary to maintain recommendation accuracy.
Over the past several decades, much has been achieved and good
progress made in understanding EGPA. Nevertheless, these recommen-
dations and the data supporting them also reveal that more research is
needed to continue to improve management of patients with this com-
plex disease.
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